FDA Approves Semaglutide (Ozempic) for Kidney Protection in Diabetes Patients with CKD

A breakthrough in diabetes and kidney care! The FDA has approved Semaglutide (Ozempic) to help reduce the risk of worsening kidney disease, kidney failure, and cardiovascular-related deaths in adults with type 2 diabetes and chronic kidney disease (CKD). This makes Ozempic the first and only GLP-1 receptor agonist approved for this indication.

Why This Approval Matters

✔ CKD affects 37 million adults in the U.S., with diabetes being the leading cause.
✔ 40% of people with type 2 diabetes also have CKD, increasing their risk of kidney failure and cardiovascular disease.
✔ Semaglutide offers a new treatment option to slow kidney disease progression and reduce major health risks.

Clinical Evidence: The FLOW Study

The approval is based on the FLOW phase 3b trial, which studied 3,533 adults with type 2 diabetes and CKD:

  • 24% lower risk of kidney disease worsening, kidney failure, and cardiovascular death.
  • 4.9% absolute risk reduction over 3 years, demonstrating significant benefits over standard treatment.
  • The trial was stopped early due to strong evidence of effectiveness.

What is Ozempic?

Ozempic (semaglutide) is an injectable GLP-1 receptor agonist used for:

Improving blood sugar control in type 2 diabetes.
Lowering the risk of heart attack, stroke, or cardiovascular death in diabetes patients with heart disease.
Now approved to slow kidney disease progression in type 2 diabetes with CKD.

Doctors and healthcare providers should consider Ozempic (Semaglutide) as a treatment option for diabetes patients with CKD.

🔹 Educate patients about kidney risks and early intervention.
🔹 Monitor kidney function regularly in diabetic patients.
🔹 Stay updated on new diabetes and CKD treatment guidelines.

This approval marks a major advancement in protecting kidney health and saving lives. Let’s work together for better patient outcomes!

To register for our next masterclass please click here https://linktr.ee/docpreneur

Melbourne, Australia
(Sat - Thursday)
(10am - 05 pm)